Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MAOA | P21397 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316302 | 0.94 | MAOA (0.66) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3312424 | 0.94 | MAOA (0.77) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3313161 | 0.94 | MAOA (0.84) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3319382 | 0.93 | MAOA (0.65) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL28674208 | 0.92 | MAOA (0.63) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3316280 | 0.89 | KMT2A (0.71) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3312412 | 0.88 | MAOA (0.75) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3313102 | 0.88 | MAOA (0.61) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL23052546 | 0.86 | KMT2A (0.64) | MAPTMAOAKMT2AMEN1RECQL | |
| SCHEMBL3312505 | 0.86 | KMT2A (0.63) | MAPTMAOAKMT2AMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | MAPT 4438/4885MAOA 181/4885KMT2A 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.